Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 16/20 | 1.00 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356028 | 0.87 | DHODH (1.00) | DHODHCLCN2LMNAGAAMEN1 | |
| SCHEMBL354131 | 0.87 | DHODH (1.00) | DHODHCLCN2LMNAGAAMEN1 | |
| Water SCHEMBL356057 | 0.86 | DHODH (0.98) | DHODHCLCN2LMNAGAAMEN1 | |
| SCHEMBL1487323 | 0.84 | DHODH (0.76) | DHODHCLCN2LMNAGAAMEN1 | |
| SCHEMBL3725645 | 0.80 | DHODH (0.72) | DHODHCLCN2LMNAGAAMEN1 | |
| Tromethamine SCHEMBL16741990 | 0.80 | DHODH (0.85) | DHODHLMNAGAAMEN1KMT2A | |
| SCHEMBL729556 | 0.78 | DHODH (0.81) | DHODHLMNAGAAMEN1NPC1 | |
| SCHEMBL3872950 | 0.78 | DHODH (0.69) | DHODH | |
| SCHEMBL729207 | 0.77 | DHODH (1.00) | DHODHCLCN2LMNAGAAMEN1 | |
| SCHEMBL729595 | 0.76 | DHODH (1.00) | DHODHLMNAGAAHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691852-B2 | Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors | AMIRALL, S.A. (ES) | 2014-04-08 | — | — | US | claimed |
| US-20120294854-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. | 2012-11-22 | — | — | US | claimed |
| EP-2121614-B1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2012-06-20 | — | — | EP | claimed |
| JP-2011524392-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110129445-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-02 | — | — | US | claimed |
| EP-2296663-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | Almirall, S.A. (ES) | 2011-03-23 | — | — | EP | claimed |
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| WO-2009153043-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-12-23 | — | — | WO | claimed |
| EP-2135610-A1 | Combination comprising DHODH inhibitors and methotrexate | Laboratorios Almirall, S.A. (ES) | 2009-12-23 | — | — | EP | claimed |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
| US-8865728-B2 | Combinations comprising methotrexate and DHODH inhibitors | ALMIRALL, S.A. (ES) | 2014-10-21 | — | — | US | disclosed |
| US-8691852-B2 | Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors | AMIRALL, S.A. (ES) | 2014-04-08 | — | — | US | disclosed |
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| WO-2009153043-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-12-23 | — | — | WO | disclosed |
| EP-2135610-A1 | Combination comprising DHODH inhibitors and methotrexate | Laboratorios Almirall, S.A. (ES) | 2009-12-23 | — | — | EP | disclosed |
| EP-2121614-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008077639-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, NQO2, DAO | DHODH 1/4885CLCN2 2129/4885LMNA 4082/4885 |
| US-20120294854-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, NQO2, DAO | DHODH 1/4885CLCN2 2129/4885LMNA 4082/4885 |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | DHODH 1/4885CLCN2 2216/4885LMNA 2709/4885 |
| US-20110129445-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | DHODH, DHFR, MTHFD2 | DHODH 1/4885CLCN2 3917/4885LMNA 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.